ArticleCancers2023

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study.

Michele Del Vecchio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.